RxDoctor Payments DataLook up a doctor →

Gigi Lefebvre, MD

Family Medicine · St Petersburg, FLNPI 1801908074

Payments from drug & device makers

$9,246,843in general payments, 2019–2025

Across 847 payments — averaging $10,917 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$4M
  • Eli Lilly$2M
  • AbbVie$1.6M
  • Johnson & Johnson$495K
  • Eisai Inc.$257K
  • Biohaven Pharmaceuticals, Inc.$209K
  • plus $649K from 18 others
$8,198in research payments, 2019–2025

Across 3 payments — averaging $2732.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$8K

What the payments were for

  • Food & beverage$123100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,246,843 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$81,603
Medicare patients
142
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$15,408
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$3,780
SynthroidLevothyroxine Sodium16$2,025
Famotidine90$1,811
Omeprazole105$1,632
Rosuvastatin Calcium145$1,605
Levothyroxine Sodium137$1,287
Calcitonin-SalmonCalcitonin,salmon,synthetic15$1,216
Nadolol16$1,198
Pravastatin Sodium60$1,057
Tramadol Hcl59$833
Gabapentin32$792
Ezetimibe50$766
Ibandronate Sodium19$682
Bupropion XlBupropion Hcl24$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39,610$15,40815 claims
AbbVieSynthroid$1,600,227$2,02516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →